Who
Matthew Buten
Chief Financial Officer
Company insider
Files Form 4 as: Chief Financial Officer, Biohaven; Chief Financial Officer, Biohaven Pharmaceutical Holding Co.
In numbers
- Trades disclosed
- 36
- Buys
- 2
- Sells
- 0
- Bought
- $2.0M
- Sold
- $0
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 8 Dec 2021
- Last trade
- 27 Feb 2026
- Last filed
- 3 Mar 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 27 Feb 2026filed 3 Mar 2026 | BHVN Biohavenoption or derivative · Biotechnology | SEC FORM 4 Code A | —175,000 at $0.00 | filing |
| 27 Feb 2026filed 3 Mar 2026 | BHVN Biohavenoption or derivative · Biotechnology | SEC FORM 4 Code A | —175,000 at $0.00 | filing |
| 5 Jan 2026filed 7 Jan 2026 | BHVN BiohavenBiotechnology | SEC FORM 4 Code M | —4,250 at $0.00 | filing |
| 5 Jan 2026filed 7 Jan 2026 | BHVN BiohavenBiotechnology | SEC FORM 4 Code F | $26K2,594 at $9.93 | filing |
| 5 Jan 2026filed 7 Jan 2026 | BHVN Biohavenoption or derivative · Biotechnology | SEC FORM 4 Code M | —4,250 at $0.00 | filing |
| 5 Jan 2026filed 7 Jan 2026 | BHVN Biohavenoption or derivative · Biotechnology | SEC FORM 4 Code M | —4,250 at $0.00 | filing |
| 5 Jan 2026filed 7 Jan 2026 | BHVN BiohavenBiotechnology | SEC FORM 4 Code M | —4,250 at $0.00 | filing |
| 5 Jan 2026filed 7 Jan 2026 | BHVN BiohavenBiotechnology | SEC FORM 4 Code F | $26K2,594 at $9.93 | filing |
| 5 Jan 2025filed 7 Jan 2025 | BHVN Biohavenoption or derivative · Biotechnology | SEC FORM 4 Code A | —104,000 at $0.00 | filing |
| 5 Jan 2025filed 7 Jan 2025 | BHVN Biohavenoption or derivative · Biotechnology | SEC FORM 4 Code A | —17,000 at $0.00 | filing |
| 5 Jan 2025filed 7 Jan 2025 | BHVN Biohavenoption or derivative · Biotechnology | SEC FORM 4 Code M | —4,250 at $0.00 | filing |
| 5 Jan 2025filed 7 Jan 2025 | BHVN BiohavenBiotechnology | SEC FORM 4 Code M | —4,250 at $0.00 | filing |
| 5 Jan 2025filed 7 Jan 2025 | BHVN BiohavenBiotechnology | SEC FORM 4 Code F | $99K2,561 at $38.64 | filing |
| 2 Jan 2024filed 4 Jan 2024 | BHVN Biohavenoption or derivative · Biotechnology | SEC FORM 4 Code A | —96,250 at $0.00 | filing |
| 2 Nov 2023filed 6 Nov 2023 | BHVN Biohavenoption or derivative · Biotechnology | SEC FORM 4 Code A | —78,750 at $0.00 | filing |
| 5 Oct 2023filed 6 Oct 2023 | BHVN BiohavenBiotechnology | SEC FORM 4 Bought | $500K22,727 at $22.00 | filing |
| 25 Oct 2022filed 26 Oct 2022 | BHVN BiohavenBiotechnology | SEC FORM 4 Bought | $1.5M142,857 at $10.50 | filing |
| 3 Oct 2022filed 5 Oct 2022 | BHVN Biohavenoption or derivative · Biotechnology | SEC FORM 4 Code J | —1,550 | filing |
| 3 Oct 2022filed 5 Oct 2022 | BHVN Biohavenoption or derivative · Biotechnology | SEC FORM 4 Code J | —11,450 | filing |
| 3 Oct 2022filed 5 Oct 2022 | BHVN Biohavenoption or derivative · Biotechnology | SEC FORM 4 Code M | —1,550 at $0.00 | filing |
News
Biohaven (BHVN) Soars 25% on FDA Drug Review, Price Target UpgradeBHVN · insidermonkey.com · 23 Oct 2026Biohaven's Troriluzole NDA Accepted For FDA Review; Decision In Q1 2027; Stock UpBHVN · rttnews.com · 22 Oct 2026Biohaven Stock Soars Nearly 30% After FDA Accepts Resubmitted Application for Rare Disease Drug VyglxiaBHVN · ibtimes.com.au · 22 Oct 2026
0 headlines in the last 90 days name Matthew Buten; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.